Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

The proposition that one can’t extract from all previous Brilacidin preclinical and clinical data a probability for success is itself patently false. Such a proposition is not simply healthy cynicism, it goes beyond that strongly into willful ignorance of data meaning and implications for successful trial outcomes.

Previous trial outcomes indicate a far stronger safety and efficacy profile than Remdesivir. Had it not been for “better than nothing” efficacy outcomes with its marginal safety, Remdesivir never would have been approved outside a world health emergency environment. The FDA had already failed to approve the drug previously following phase 3 studies.

Brilacidin is safer and shows efficacy profiles stronger than Remdesivir’s. One can easily assess a good likelihood for emergency approval. After all, it only has to be demonstratively better than both nothing and Remdesivir. Is it a slam dunk? No. But it’s much better odds than average.